The Experts below are selected from a list of 84 Experts worldwide ranked by ideXlab platform
Kirsten D. Mertz - One of the best experts on this subject based on the ideXlab platform.
-
Grover’s-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy
Journal for ImmunoTherapy of Cancer, 2016Co-Authors: Viktor H. Koelzer, Tobias Buser, Niels Willi, Sacha I. Rothschild, Andreas Wicki, Peter Schiller, Gieri Cathomas, Alfred Zippelius, Kirsten D. MertzAbstract:Background Dermatologic toxicity is an important adverse effect of immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death 1 receptor (PD-1) or PD ligand 1 (PD-L1). Skin toxicity most commonly includes a maculopapular erythematous rash and pruritus. Rarely life threatening complications such as Steven’s Johnson syndrome or toxic epidermal necrolysis may occur. Case presentation Here we report the uncommon event of a drug-induced Transient Acantholytic Dermatosis (Grover’s disease) in a 73-year-old Caucasian male treated with ipilimumab for metastatic melanoma. Five weeks after initiation of therapy, the patient developed a widespread polymorphic papulovesicular Dermatosis on the trunk and proximal extremities with intense pruritus. Skin biopsy showed Acantholytic dyskeratosis with interface dermatitis consistent with a Grover’s-like drug eruption. Conclusions These findings should raise awareness for uncommon immune-related dermatological toxicities of immunomodulatory antibodies targeting the CTLA-4 signaling axis. We recommend biopsies of unexpected skin lesions to rapidly identify dermatological adverse events of immune checkpoint inhibitors.
Thomas L Dawson - One of the best experts on this subject based on the ideXlab platform.
-
skin diseases associated with malassezia species
Journal of The American Academy of Dermatology, 2004Co-Authors: Aditya K Gupta, Roma Batra, Robyn Bluhm, Teun Boekhout, Thomas L DawsonAbstract:Abstract The yeasts of the genus Malassezia have been associated with a number of diseases affecting the human skin, such as pityriasis versicolor, Malassezia ( Pityrosporum ) folliculitis, seborrheic dermatitis and dandruff, atopic dermatitis, psoriasis, and—less commonly—with other dermatologic disorders such as confluent and reticulated papillomatosis, onychomycosis, and Transient Acantholytic Dermatosis. Although Malassezia yeasts are a part of the normal microflora, under certain conditions they can cause superficial skin infection. The study of the clinical role of Malassezia species has been surrounded by controversy because of their fastidious nature in vitro, and relative difficulty in isolation, cultivation, and identification. Many studies have been published in the past few years after the taxonomic revision carried out in 1996 in which 7 species were recognized. Two new species have been recently described, one of which has been isolated from patients with atopic dermatitis. This review focuses on the clinical, mycologic, and immunologic aspects of the various skin diseases associated with Malassezia . It also highlights the importance of individual Malassezia species in the different dermatologic disorders related to these yeasts.
Viktor H. Koelzer - One of the best experts on this subject based on the ideXlab platform.
-
Grover’s-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy
Journal for ImmunoTherapy of Cancer, 2016Co-Authors: Viktor H. Koelzer, Tobias Buser, Niels Willi, Sacha I. Rothschild, Andreas Wicki, Peter Schiller, Gieri Cathomas, Alfred Zippelius, Kirsten D. MertzAbstract:Background Dermatologic toxicity is an important adverse effect of immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death 1 receptor (PD-1) or PD ligand 1 (PD-L1). Skin toxicity most commonly includes a maculopapular erythematous rash and pruritus. Rarely life threatening complications such as Steven’s Johnson syndrome or toxic epidermal necrolysis may occur. Case presentation Here we report the uncommon event of a drug-induced Transient Acantholytic Dermatosis (Grover’s disease) in a 73-year-old Caucasian male treated with ipilimumab for metastatic melanoma. Five weeks after initiation of therapy, the patient developed a widespread polymorphic papulovesicular Dermatosis on the trunk and proximal extremities with intense pruritus. Skin biopsy showed Acantholytic dyskeratosis with interface dermatitis consistent with a Grover’s-like drug eruption. Conclusions These findings should raise awareness for uncommon immune-related dermatological toxicities of immunomodulatory antibodies targeting the CTLA-4 signaling axis. We recommend biopsies of unexpected skin lesions to rapidly identify dermatological adverse events of immune checkpoint inhibitors.
Niels Willi - One of the best experts on this subject based on the ideXlab platform.
-
Grover’s-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy
Journal for ImmunoTherapy of Cancer, 2016Co-Authors: Viktor H. Koelzer, Tobias Buser, Niels Willi, Sacha I. Rothschild, Andreas Wicki, Peter Schiller, Gieri Cathomas, Alfred Zippelius, Kirsten D. MertzAbstract:Background Dermatologic toxicity is an important adverse effect of immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death 1 receptor (PD-1) or PD ligand 1 (PD-L1). Skin toxicity most commonly includes a maculopapular erythematous rash and pruritus. Rarely life threatening complications such as Steven’s Johnson syndrome or toxic epidermal necrolysis may occur. Case presentation Here we report the uncommon event of a drug-induced Transient Acantholytic Dermatosis (Grover’s disease) in a 73-year-old Caucasian male treated with ipilimumab for metastatic melanoma. Five weeks after initiation of therapy, the patient developed a widespread polymorphic papulovesicular Dermatosis on the trunk and proximal extremities with intense pruritus. Skin biopsy showed Acantholytic dyskeratosis with interface dermatitis consistent with a Grover’s-like drug eruption. Conclusions These findings should raise awareness for uncommon immune-related dermatological toxicities of immunomodulatory antibodies targeting the CTLA-4 signaling axis. We recommend biopsies of unexpected skin lesions to rapidly identify dermatological adverse events of immune checkpoint inhibitors.
Sacha I. Rothschild - One of the best experts on this subject based on the ideXlab platform.
-
Grover’s-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy
Journal for ImmunoTherapy of Cancer, 2016Co-Authors: Viktor H. Koelzer, Tobias Buser, Niels Willi, Sacha I. Rothschild, Andreas Wicki, Peter Schiller, Gieri Cathomas, Alfred Zippelius, Kirsten D. MertzAbstract:Background Dermatologic toxicity is an important adverse effect of immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death 1 receptor (PD-1) or PD ligand 1 (PD-L1). Skin toxicity most commonly includes a maculopapular erythematous rash and pruritus. Rarely life threatening complications such as Steven’s Johnson syndrome or toxic epidermal necrolysis may occur. Case presentation Here we report the uncommon event of a drug-induced Transient Acantholytic Dermatosis (Grover’s disease) in a 73-year-old Caucasian male treated with ipilimumab for metastatic melanoma. Five weeks after initiation of therapy, the patient developed a widespread polymorphic papulovesicular Dermatosis on the trunk and proximal extremities with intense pruritus. Skin biopsy showed Acantholytic dyskeratosis with interface dermatitis consistent with a Grover’s-like drug eruption. Conclusions These findings should raise awareness for uncommon immune-related dermatological toxicities of immunomodulatory antibodies targeting the CTLA-4 signaling axis. We recommend biopsies of unexpected skin lesions to rapidly identify dermatological adverse events of immune checkpoint inhibitors.